STOCK TITAN
  1. Home
  2. News
  3. SRDX

Surmodics, Inc. - SRDX STOCK NEWS

Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.

Surmodics, Inc. (NASDAQ: SRDX) is a dynamic player in the healthcare industry, partnering with both established and emerging medical device, diagnostic, and life sciences companies. The company specializes in developing and commercializing innovative products aimed at improving lives through better disease detection and treatment.

Surmodics operates under two main segments: the Medical Device unit and the Vitro Diagnostics unit. The Medical Device unit primarily focuses on performance coatings and surface modification technologies. Recently, Surmodics has expanded its role from being a provider of coating technologies to offering complete product solutions thanks to strategic acquisitions.

In the Vitro Diagnostics unit, Surmodics manufactures chemical and biological components used in a variety of in vitro diagnostic immunoassay and molecular tests, serving the diagnostic and biomedical research markets. This segment plays a crucial role in the healthcare industry by providing essential materials for disease detection and research.

Surmodics' mission is steadfast: to enhance the detection and treatment of diseases by leveraging its technology to address complex challenges in the medical device and diagnostic fields. The company is committed to fostering innovation and advancing healthcare solutions, ensuring they remain at the forefront of the industry.

Recent Achievements:

  • Successful integration of acquired companies, enhancing their whole-product solutions capability.
  • Development of cutting-edge diagnostic technologies improving the accuracy and efficiency of disease detection.
  • Establishment of key partnerships with industry leaders to drive innovation and expand market reach.

Current Projects:

  • Advancing their surface modification technologies to meet evolving medical needs.
  • Expanding their product portfolio to provide comprehensive solutions in the medical device sector.
  • Ongoing research and development to innovate and improve diagnostic components.

Surmodics is well-positioned financially, with the majority of its revenue derived from its Medical Device segment. This financial stability supports their ongoing commitment to innovation and excellence in the healthcare industry.

News

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

Rhea-AI Summary
Surmodics, Inc. (SRDX) announces the successful early clinical use of the Pounce LP Thrombectomy System, a low-profile device designed for efficient clot removal in peripheral arteries ranging from 2 mm to 4 mm. The system received FDA clearance in June 2023 and is currently in limited market evaluation, with full commercial launch planned following completion of the LME. The Pounce LP System complements the original Pounce Thrombectomy System, introduced in 2021, and is indicated for use in vessels below the knee. Early clinical use has shown positive results, with vascular surgeons praising the device's effectiveness in treating chronic thrombus in complex lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
News

Surmodics to Host Virtual Annual Meeting of Shareholders

Rhea-AI Summary
Surmodics, Inc. (SRDX) will hold its Annual Meeting of Shareholders on February 8, 4 p.m. CT. The virtual meeting will be led by Chair of the Board, Sue Knight, and President/CEO Gary Maharaj will provide business updates. To attend, visit www.virtualshareholdermeeting.com/SRDX24. A webcast replay will be available until February 9, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
News

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Rhea-AI Summary
Surmodics, Inc. (SRDX) will release its first quarter fiscal year 2024 financial results on February 1, followed by a conference call and webcast to discuss the results and accomplishments. The live webcast will be accessible through the company's website, while the teleconference can be accessed by dialing a provided number. An audio replay of the conference call will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences earnings
News

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announces promising 24-month data from the SWING Trial on the Sundance™ Sirolimus Drug-Coated Balloon (DCB) for treating occlusive disease of the infrapopliteal arteries. The trial achieved its primary safety and efficacy endpoints, showcasing a 71.4% primary patency rate at 24 months in the per protocol analysis population. The results were presented at the 50th annual VEITH Symposium in New York, New York, demonstrating an excellent safety profile with sustained positive outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
News

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced the 36-month data from its TRANSCEND clinical trial, presenting the safety and efficacy of the SurVeil drug coated balloon (DCB) compared to the IN.PACT Admiral DCB for treating superficial femoral and proximal popliteal artery lesions. The primary efficacy and safety endpoints showed comparable outcomes, demonstrating the non-inferiority of the SurVeil DCB to the IN.PACT Admiral DCB. Dr. Peter A. Schneider presented the data at the 50th Annual VEITH Symposium in New York, New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
News

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

Rhea-AI Summary
Surmodics, Inc. (SRDX) to Participate in 35th Annual Piper Sandler Healthcare Conference. The company's management will present at the conference on November 28, 2023, and a live webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
News

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

Rhea-AI Summary
SRDX: Surmodics Reports Strong Financial Results and Fiscal 2024 Guidance, Announces New Product Launches and Clinical Trial Data
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
earnings
-
News

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Rhea-AI Summary
Surmodics, Inc. will present 24-month data from the SWING Trial, evaluating the Sundance™ Sirolimus Drug-Coated Balloon's safety and performance in treating occlusive lesions in the infra-popliteal arteries. The trial reports an 8.3% major adverse event rate at 6 months and an 80% target lesion primary patency rate at 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
News

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
News

Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications

Rhea-AI Summary
Surmodics, Inc. has launched Preside hydrophilic coatings, its most advanced medical device coating technology. The coatings offer low-friction and low-particulate generation, improving distal access for neurovascular applications and crossing for challenging coronary lesions. The coatings are formulated to balance enhanced lubricity and coating durability. Surmodics has secured the first 510(k) device clearance for this technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none

FAQ

What is the current stock price of Surmodics (SRDX)?

The current stock price of Surmodics (SRDX) is $39.17 as of November 20, 2024.

What is the market cap of Surmodics (SRDX)?

The market cap of Surmodics (SRDX) is approximately 551.0M.

What does Surmodics, Inc. specialize in?

Surmodics, Inc. specializes in surface modification and in vitro diagnostic technologies for the healthcare industry.

What are the main business segments of Surmodics, Inc.?

Surmodics operates in two main segments: the Medical Device unit, focusing on performance coatings, and the Vitro Diagnostics unit, manufacturing diagnostic components.

What is the mission of Surmodics, Inc.?

The mission of Surmodics is to improve the detection and treatment of diseases by providing innovative solutions to complex medical device and diagnostic challenges.

Who does Surmodics, Inc. partner with?

Surmodics partners with leading and emerging medical device, diagnostic, and life sciences companies to develop and commercialize innovative healthcare products.

Where does Surmodics, Inc. derive the majority of its revenue from?

Surmodics derives the majority of its revenue from its Medical Device segment.

What recent achievements has Surmodics, Inc. accomplished?

Recent achievements include successful acquisitions, enhanced whole-product solutions, and advancements in diagnostic technologies.

What current projects is Surmodics, Inc. working on?

Current projects include advancing surface modification technologies, expanding their medical device product portfolio, and ongoing R&D in diagnostic components.

How is Surmodics, Inc. contributing to the healthcare industry?

Surmodics contributes to the healthcare industry by innovating in medical device coatings and diagnostic technologies, improving disease detection and treatment.

What role does the Vitro Diagnostics unit play in Surmodics, Inc.?

The Vitro Diagnostics unit manufactures chemical and biological components for diagnostic tests, playing a crucial role in disease detection and biomedical research.

How is Surmodics, Inc. positioned financially?

Surmodics is financially stable, primarily driven by its revenues from the Medical Device segment, supporting its commitment to innovation and excellence.

Stock SRDX logo
Surmodics, Inc.

Nasdaq:SRDX

SRDX Rankings

#3020 Ranked by Market Cap
N/A Ranked by Dividends

SRDX Stock Data

550.99M
13.66M
3.8%
83.42%
2.32%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
EDEN PRAIRIE